Sentences with phrase «tumor patient who»

Not exact matches

It will focus its initial clinical sequencing efforts on cancer, teaming up with the Moores Cancer Center at the University of California, San Diego to sequence the genomes of every patient who is treated there, as well as perform a full genome sequence on their tumors.

They are finding cancerous tumors that are in phase 0 and 1 in patients who are experiencing no pain, whereas most people are often diagnosed in phase 4, where pain is prevalent and the disease is more difficult to beat.

MEG TIRRELL, NIGHTLY BUSINESS REPORT CORRESPONDENT: Since they were approved in 2014, drugs that stimulate the immune system have been giving new hope to patients with melanoma, kidney cancer, lymphoma and other cancers, including famously to President Jimmy Carter, who credited the drug called Keytruda with shrinking tumors that had spread to his brain.

The targeted radiotherapy shrank tumors for 71 % of patients who had already failed standard chemotherapy, but these results came from a small trial that started with 30 patients and then added another 20 after positive data started rolling in.

Maybe you are a surgeon who was once content to use your surgical skills on your cancer patients to remove tumors while letting the patient adjust to the process the best she or he could.

Surely, for a patient who can no longer assimilate food, N&H provides no benefit; similarly, some stomach cancer cases result in feeding the tumor instead of the patient; and there are those who are so fragile that almost any invasive insert causes more problems than it relieves.

They do NOT claim that soy CAUSES cancer... only that substantial research exists that shows it accelerates the growth and multiplicity of tumors in patients who already have cancer.

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therapies.

«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.

Currently, many patients who acquire resistance to EGFR - targeted therapy undergo a tumor biopsy and are designated as either positive or negative for specific secondary mutations.

Matching unique genetic information from cancer patients» tumors with treatment options — an emerging area of precision medicine efforts — often fails to identify all patients who may respond to certain therapies.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

This study analyzed preserved tumor samples from 43 prostate cancer patients who later received radiation therapy after rising PSA levels were detected following a radical prostatectomy.

«The ability to address any solid tumors that can be surgically removed greatly increases the number of patients who might benefit from such potent immune - stimulating agents, which can be toxic when administered throughout the body.

«For patients who have not responded to prior therapies, this drug now provides a very real chance to shrink their tumors and the hope of a lasting response to treatment.»

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancer.

In particular, the study suggests that two miRNAs — miR - 4516 and miR - 601 — in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapy.

Additionally, lung cancer patients who have high levels of YAP1 in their tumors are more likely to have a poorer prognosis than patients with low levels of YAP1.

They are working together to mesh her identification of compounds that target tumors with runaway Ras activity and tumor data (analyzed by machine learning) to find patients who could benefit from these potential cancer drugs.

To Kalish, the patients who are diagnosed with the syndrome after they develop cancer, like the little girl whose adrenal tumor set off alarm bells, have her wondering whether the incidence of Beckwith - Wiedemann is higher than reported.

In other words, regardless of surgery timing, patients who require higher risk procedures, such as a major liver resection due to the presence of larger or multiple metastatic tumors or high - risk colorectal resections, have poorer outcomes than those who underwent more minor surgery.

In 2002 scientists showed that cytomegalovirus, or CMV, was active in the brain tumors but not the surrounding healthy tissue of all 27 patients they tested who had glioblastoma multiforme.

Indeed, all of the tumors from patients who carried this particular T - to - A mutation also had additional mutations that inactivate the APC gene.

Although surgery that is confined to removing just a small tumor (loco - regional treatment) is generally considered to be low risk, we have previously demonstrated that the proportion of patients who develop postoperative complications strongly increases with age and increasing numbers of other diseases or conditions that they may have.

The researchers analyzed the samples using immunohistochemistry and RNA sequencing to study the changes in the tumor immune microenvironment of patients who received and did not receive chemotherapy, and changes before and after chemotherapy.

BRAF inhibitors are a first line of treatment for melanoma patients who harbor the BRAF mutation, which is an abnormal change in a gene that causes some melanoma tumors to grow and spread more aggressively.

The 15 AACR scientists, who were already in Washington, D.C., to meet with the U.S. Food and Drug Administration on genetic testing for cancer patients, tossed around ideas including expanding NCI's tumor genome - sequencing efforts and getting the government to cover the costs of genomic tumor profiling.

«After just three treatment cycles, we saw tumor markers plummet and some patients» tumors shrink significantly in just nine weeks,» said Gayle Jameson, nurse practitioner and principal investigator of the clinical trial, who is highly encouraged by the response.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

The study demonstrated a trend toward a reduction in the incidence of tumor recurrence in patients who had pelvic RT..

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

This study of 37 patients (24 men and 13 women, ages 51 to 80) who have never been treated with chemotherapy found direct correlation of the amount of cfDNA with tumor metabolism (based on PET - derived parameters), but not with metabolic tumor volume.

«This is the first time the 3 - D culturing method has been used to predict the effectiveness of different drugs on tumors from individual patients,» said graduate student Alex Walsh, who has played a key role in developing the test.

The trial investigated the drug in two separate cohorts of patients: Cohort A, which included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD - L1 expression, and Cohort B, which included 52 patients with PD - L1 - positive tumors who received it as first - line therapy.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

The researchers next will turn to analyzing the presence of myoferlin in samples from numerous human tumor types available in an Ohio State tissue bank, which will allow them to compare protein levels in tumors to clinical outcomes for the patients who provided the samples.

Patients with aggressive neuroendocrine tumors (NETs) have limited treatment options and there are few oncologists who are specialised in this relatively rare disease.

In recent studies of cancer patients who received a bone marrow transplant, genes from the marrow's white blood cells were found in the patient's tumor cells.

The good bacteria seem to help the drugs by priming T cells, which Wargo's group reported were more abundant in the gut and tumors of the mice who got fecal transplants from responder patients.

«The good news is that we discovered that a subset of patients who had both high tumor mutation burden and high PDL - 1 positive status did experience a significant benefit from immunotherapy,» says Carbone.

The team reports that Sema3D was abundant in the main tumor tissue of only three of 13 (23 percent) patients who died after minimal cancer spread.

In one instance, the scientists used the mutational signature to uncover an artistolochic - related tumor in a patient who was unaware of prior exposure.

But it was abundant in the main tumors of 14 of 22 (64 percent) patients who died with widely metastatic cancer, and also in the metastatic tumors of 17 of 23 (74 percent) patients.

In a 2011 vaccine trial of patients whose primary pancreatic tumors were surgically removed, «we found antibodies against annexin A2 in those who had received the vaccine and who also had demonstrated long - term, disease - free survival after receiving the vaccines,» explains Zheng.

A team of researchers in Baltimore tested tumor tissue and healthy tissue from 815 patients who had various cancers.

Of the several thousand cancer patients treated annually at the Heidelberg National Center for Tumor Diseases (NCT), whole - genome sequencing of tumors is offered to all patients who might benefit, says Eils.

Surprisingly, they found that although the patterns of gene expression — as shown by the RNA sequencing — differed between the hepatocellular carcinomas and the liver cancers with biliary phenotype and depended on the histological type, the overall pattern of mutations in the cells was actually similar between the tumors — of either type — that had emerged in patients who had had infections with either hepatitis C or B, and were different in patients without such infections.

«The results were remarkable, with significant shrinkage in patient - derived tumors,» said Memarzadeh, who also is an associate professor of obstetrics and gynecology and the director of the G.O. Discovery Laboratory at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and associate professor.